JP2005531280A - 赤血球生成障害用治療薬および診断薬 - Google Patents

赤血球生成障害用治療薬および診断薬 Download PDF

Info

Publication number
JP2005531280A
JP2005531280A JP2003540394A JP2003540394A JP2005531280A JP 2005531280 A JP2005531280 A JP 2005531280A JP 2003540394 A JP2003540394 A JP 2003540394A JP 2003540394 A JP2003540394 A JP 2003540394A JP 2005531280 A JP2005531280 A JP 2005531280A
Authority
JP
Japan
Prior art keywords
gene
erythropoiesis
protein
cells
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003540394A
Other languages
English (en)
Japanese (ja)
Inventor
ウィリアム エイチ． ブリッセット，
カルディープ エス． ネオーテ，
パナイオティス ザゴラス，
マルティン ツェンケ，
ブリット レムケ，
クリスティーネ ハッカー，
Original Assignee
ファイザー・プロダクツ・インク
マックス−デルブルック−センター フォア モレキュラー メディシン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・プロダクツ・インク, マックス−デルブルック−センター フォア モレキュラー メディシン filed Critical ファイザー・プロダクツ・インク
Publication of JP2005531280A publication Critical patent/JP2005531280A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2003540394A 2001-10-31 2002-10-31 赤血球生成障害用治療薬および診断薬 Withdrawn JP2005531280A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33504801P 2001-10-31 2001-10-31
US33518301P 2001-11-02 2001-11-02
PCT/US2002/034888 WO2003038130A2 (fr) 2001-10-31 2002-10-31 Solutions therapeutiques et diagnostiques pour les troubles de l'erythropoiese

Publications (1)

Publication Number Publication Date
JP2005531280A true JP2005531280A (ja) 2005-10-20

Family

ID=26989530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003540394A Withdrawn JP2005531280A (ja) 2001-10-31 2002-10-31 赤血球生成障害用治療薬および診断薬

Country Status (7)

Country Link
US (1) US20040014064A1 (fr)
EP (1) EP1446507A2 (fr)
JP (1) JP2005531280A (fr)
CA (1) CA2460283A1 (fr)
IL (1) IL160905A0 (fr)
MX (1) MXPA04003382A (fr)
WO (1) WO2003038130A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7847060B2 (en) 2005-02-25 2010-12-07 Oncotherapy Science, Inc. Peptide vaccines for lung cancers expressing TTK, URLC10 or KOC1 polypeptides

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE364690T1 (de) 2001-11-09 2007-07-15 Proteologics Inc Posh nukleinsäure, polypeptide und darauf bezogene verfahren
CA2535976A1 (fr) * 2003-08-20 2005-03-03 Cleveland Clinic Foundation Nouveau gene et proteine associe a l'angiogenese et a l'apoptose endotheliale
DE102004062281A1 (de) * 2003-12-29 2005-07-28 Siemens Ag Verfahren und Spotting-Lösung zum Herstellen von Microarrays
FR2914304B1 (fr) * 2007-03-28 2012-11-16 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de vcam.
US8119366B2 (en) * 2007-10-05 2012-02-21 Trojan Technologies, Ltd. Antennapedia-dominant negative mastermind-like construct
WO2012078967A2 (fr) * 2010-12-10 2012-06-14 Alnylam Pharmaceuticals, Inc. Compositions et procédés pour l'augmentation de la production d'érythropoïétine (epo)
JO3623B1 (ar) 2012-05-18 2020-08-27 Amgen Inc البروتينات المرتبطة بمولد المستضاد st2
WO2022221462A1 (fr) * 2021-04-13 2022-10-20 Kriya Therapeutics, Inc. Constructions de vecteur pour l'administration d'acides nucléiques codant pour une vlcad ou une mcad thérapeutique et leurs procédés d'utilisation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) * 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5252743A (en) * 1989-11-13 1993-10-12 Affymax Technologies N.V. Spatially-addressable immobilization of anti-ligands on surfaces
US6051380A (en) * 1993-11-01 2000-04-18 Nanogen, Inc. Methods and procedures for molecular biological analysis and diagnostics
EP0916396B1 (fr) * 1991-11-22 2005-04-13 Affymetrix, Inc. (a Delaware Corporation) Stratégies associées pour la synthèse de polymères
US5412087A (en) * 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5384261A (en) * 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
WO1995008654A1 (fr) * 1993-09-24 1995-03-30 The Ishizuka Research Institute, Ltd. Materiau composite et procede pour sa production
US5631734A (en) * 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
US5571639A (en) * 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5599695A (en) * 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US5624711A (en) * 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
DE69720041T2 (de) * 1996-11-14 2004-01-08 Affymetrix, Inc., Santa Clara Chemische amplifizierung zur synthese von musterordnungen
AU9200298A (en) * 1997-08-22 1999-03-16 Yale University A process to study changes in gene expression in stem cells
US6263287B1 (en) * 1998-11-12 2001-07-17 Scios Inc. Systems for the analysis of gene expression data
WO2001012663A2 (fr) * 1999-08-19 2001-02-22 Curagen Corporation Facteurs de regulation hematopoietique et procedes d'utilisation
US6420153B1 (en) * 2000-02-29 2002-07-16 Millennium Pharmaceuticals, Inc. 18232, a novel dual specificity phosphatase and uses therefor
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7847060B2 (en) 2005-02-25 2010-12-07 Oncotherapy Science, Inc. Peptide vaccines for lung cancers expressing TTK, URLC10 or KOC1 polypeptides
US8614176B2 (en) 2005-02-25 2013-12-24 Oncotherapy Science, Inc. Peptide vaccines for lung cancers expressing TTK, URLC10 or KOC1 polypeptides

Also Published As

Publication number Publication date
IL160905A0 (en) 2004-08-31
CA2460283A1 (fr) 2003-05-08
WO2003038130A2 (fr) 2003-05-08
MXPA04003382A (es) 2004-11-22
WO2003038130A3 (fr) 2004-02-12
EP1446507A2 (fr) 2004-08-18
WO2003038130A8 (fr) 2004-04-22
US20040014064A1 (en) 2004-01-22

Similar Documents

Publication Publication Date Title
JP6448149B2 (ja) 肝線維症に関連する遺伝的多型、その検出方法および使用
JP6749431B2 (ja) 心臓血管障害および薬物応答に関連した遺伝子多型、それらの検出方法および用途
US20100151466A1 (en) Diagnosis and treatment of cervical cancer
US20030087259A1 (en) Methods and compositions for regulating bone and cartilage formation
AU2023237051A1 (en) Oligonucleotide probes and uses thereof
US8158347B2 (en) Determination of molecular age by detection of INK4a/ARF expression
JP2004159640A5 (ja) 悪性腫瘍の予測、診断、予後判定、予防および治療のための方法および組成物
US20100056445A1 (en) Adiponectin for the treatment and diagnosis of albuminuria
JP2005531281A (ja) 肺癌の治療および診断
JP2006246823A (ja) 造血因子としてのＦｇｆ２１の使用
JP2005531280A (ja) 赤血球生成障害用治療薬および診断薬
US7251568B2 (en) Methods and compositions for regulating bone and cartilage formation
JP2006523444A (ja) 骨芽細胞分化に関連する遺伝子発現
US20100143379A1 (en) Mif agonists and antagonist and therapeutic uses thereof
WO2008042510A2 (fr) Gènes et produits génétiques exprimés de façon différentielle pendant une insuffisance cardiaque
JPWO2007086515A1 (ja) 遺伝子発現解析ツール
US20050244849A1 (en) Screening assays for rheumatoid arthritis
US20040235019A1 (en) Diagnostics and therapeutics for the gene expression signature of PPAR-gamma receptor ligand
US20050037369A1 (en) Panels of molecular targets differentially expressed during CD8+ T cell priming, and methods for therapy and diagnosis utilizing the same
WO2009045403A2 (fr) Régulation par la ménine de la prolifération des cellules d'îlots bêta
JP4616178B2 (ja) 薬物の毒性予測方法
US20100129790A1 (en) Method for Determining Phospholipidosis
US20040161765A1 (en) Methods and compositions for identifying disease genes using nonsense-mediated decay inhibition
CN108085383B (zh) 基因检测组合物及其应用
JP4819791B2 (ja) リン脂質症の判定方法

Legal Events

Date Code Title Description
A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20060110